Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?
Recorded April 21, 2020.
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?
Recorded April 24, 2020.
William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and review...
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24,...
Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, and a member of The ASCO Post Editorial Board, discusses the ways in which COVID-19 has affecte...